LISNR Announces Partnership with Synchrony Financial; Selected As CES 2018 Innovation Awards Honoree

Lisnr, a Serra Capital II portfolio company, has made some exciting announcements in the month of November.  LISNR announced it has secured a strategic investment from Synchrony Financial, a premier consumer financial services company. Additionally, LISNR shared that it has been selected as a CES 2018 Innovation Awards Honoree in the Software and Mobile Apps category for the second year in a row. The CES Innovation Awards is an annual competition honoring outstanding design and engineering in consumer technology products.

LISNR is the leading global provider of data-over-audio technology, a high frequency, inaudible Smart Tone technology; a new communication protocol that sends data over audio.



Inprentus Partners with NASA

Inprentus, a Serra Capital II portfolio company, has announced that it has partnered with NASA Goddard Space Flight Center. Inprentus manufactures blazed diffraction gratings for x-ray and extreme ultraviolet light (EUV).

Through its Heliophysics Technology and Instrument Development for Science, or H-TIDeS, program, Inprentus will provide mechanically ruled, high line density, ultra-low micro roughness, blazed gratings to observe extreme ultraviolet (EUV) radiation environments such as the solar corona. Inprentus will provide four iterations of diffraction gratings for evaluation.


Chicago Bears’ Prince Amukamara Invests In Opendorse

Opendorse, a Serra Capital III portfolio company, has received an investment from Bears player Prince Amukamara, who is participating in the company's $3.5M Series A financing round. More than a third of the financing is coming from Amukamara and former Husker football players.

Opendorse connects marketers with athletes to secure sponsored social media activations from the world's most influential athletes. The company was co-founded back in 2013 by Amukamara’s ex-teammates — Blake Lawrence and Adi Kunalic.


New Patent Issued to Nanomedical Diagnostics

Nanomedical Diagnostics, a Serra Capital II portfolio company, announced a new patent issued to the company on Oct 17. The new patent is for the use of graphene biosensors with DNA probes to identify DNA sequences for precision medicine, and will enable the company’s technology to bring the benefits of lower costs, easier process, and higher throughput to the world of liquid biopsy and other DNA detection applications.

Nanomed is a life science company that has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers sensitive real-time direct detection of biomolecules. As the world’s only mass-manufacturer of graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and diagnostic and health monitoring platforms.


Chris Crocker Joins HomeBay

HomeBay, a Serra Capital III portfolio company, announced on Oct. 24 that it has welcomed Chris Crocker to the team. Crocker is the former VP of Strategic Partnerships at Zillow, as well as the former Chief Operating Office at Pacific Sotheby's, and brings more than 20 years' experience to the HomeBay team.

HomeBay helps sellers to navigate the real estate process via automated & live help to make the listing, selling and closing processes faster, easier and less stressful. The company also puts homes in front of millions of buyers by syndicating the listings to the MLS and the most popular real estate sites across the web.

"We're thrilled for Chris to join the Home Bay team. We've admired Chris for his leadership as well as his perspective and approach in advocating and leveraging technology to help partners," said Home Bay co-founder Tom Owen. "We place tremendous value on fostering great partnerships and building innovative products that support our partners. Chris is the right choice to lead this critical role."


Clarify Medical Announces Partnership With DermatologistOnCall

Clarify Medical, a Serra Capital III portfolio company, has partnered with DermatologistOnCall to to Innovate the Treatment of Chronic Skin Conditions. Clarify Medical  is a connected device that uses cutting edge LED technology to bring personal, private prescription phototherapy to patients with psoriasis, eczema and vitiligo.

“We are delighted to be working with DermatologistOnCall,” said Charlene Kakimoto MD, Clarify Medical’s Chief Medical Officer. “More than 25 percent of the patients we’ve engaged with do not have a dermatologist, and have asked for our help in finding one. DermatologistOnCall will provide an ideal response for this ongoing need, especially in areas of the country where office visits involve long wait or travel times. Together we have a fantastic opportunity to improve care for appropriate patients with chronic skin conditions. Our Clarify CarePartners, through the Clarify App, will help make sure that busy practices are diagnosing patients and managing their care, not dealing with questions about home phototherapy.”

HomeBay Brings Florida Home Sellers and Buyers Significant Costs Savings

HomeBay, a Serra Capital III portfolio company, has expanded to Florida. Home Bay offers consumers a new way to buy and sell homes without commission fees, saving its customers an average of $16,000 per transaction. HomeBay is a technology driven real estate company that helps sellers to navigate the real estate process via automated & live help to make the listing, selling and closing processes faster, easier and less stressful.

"Consumers using traditional agents are a very dissatisfied group. Even when consumers like the agent, they understandably hate the fees. Intuitively, consumers understand that three to six percent of the price of their home is way too much.," said Tom Owen, co-founder of HomeBay. "Based on our strong adoption and success, we believe consumers are eager for a superior solution at a fraction of the cost."


Inprentus to Supply Shanghai Synchrotron Radiation Facility

Inprentus, a Serra Capital II portfolio company, has been awarded a contract to supply the Shanghai Synchrotron Radiation Facility (SSRF) with three custom designed blazed diffraction gratings for use at beamlines within SSRF. Inprentus designs, manufactures and sells X-ray and EUV diffraction gratings for synchrotron radiation facilities that are used for a variety of scientific and commercial applications by many Fortune 500 companies, academic institutions and government laboratories around the world.

Ron van Os, CEO of Inprentus, commented, "Market demand is growing for Inprentus diffraction grating products throughout Asia. With this win at SSRF, Inprentus has shown that its advanced specifications and custom design capabilities are a winning combination in the synchrotron market."


ANDalyze Demonstrated its Water Quality Measurement Technology at WATEC

ANDalyze, a Serra Capital I portfolio company, demonstrated its water quality measurement technology at the Water Technology and Environmental Control (WATEC) Conference in Tel Aviv, Israel in September. 

ANDalyze has developed a superior methodology for detecting and quantifying analyte levels based on the discovery of the catalytic property of DNA (DNAzymes). This biosensor technology is a universal platform that offers a simple, fast, inexpensive, and reliable detection of trace metals and other analytes.



Asto Ct's scanner could be lifesaver for horses

Asto CT, a Serra Capital III portfolio company, was recently featured in the Wisconsin State Journal. The Asto CT Equina™ offers a paradigm shift in equine x-ray CT imaging by providing rapid 3D imaging of the lower limbs and head without subjecting the horses to general anesthesia.  With its high-precision robotic technology, the Equina™ is capable of safely imaging the lower limbs under load, as well as the head and neck of the standing horse in a single series.

Fractures for horses can be deadly and hard to detect. Often it happens that by the time the broken bone is detected, it is too late and the horse must be put down. Asto CT is trying to change this with their revolutionary scanner. It indeed will be a lifesaver for horses if the company is successful. 


Spatial a finalist for BMW startup challenge

Spatial, a Serra Capital III portfolio company, was announced on September 20 as a finalist in the BMW Startup Challenge. Spatial combines machine-assisted analysis and human-driven data like social media content to provide a cultural map of cities.  Spatial's cultural overlays make maps more useful for many industries including automobile navigation, real estate, apartment search, vacation rental and many more.

Spatial is one of two US companies selected, and each finalist will present their technologies to a jury of leading innovators in the startup world. The top three startups, selected from those 10 finalists, will then be invited to present their innovations to a live audience consisting of international journalists and entrepreneurs in a special BMW Startup Symposium in Amsterdam on September 26th.


Ringr Featured on

Ringr, a Serra Capital II portfolio company, was featured on on September 15. Ringr offers a free and premium software application which allows users to record studio-quality audio interviews. The technology eliminates staticky phone calls on the radio or warbly internet audio on podcasts. The Ringr technology changes the whole interview experience.

The article showcases how with Ringr, you can record a podcast Interview with a guest using nothing but a smartphone. 


Nanomedical Diagnostics' Agile R100 Detects Zika

Nanomedical Diagnostics, a Serra Capital II portfolio company, has announced a new publication in Biosensors and Bioelectronics demonstrating detection of Zika viral antigen using their label-free Agile R100 biosensor.  Nano is a cutting-edge life science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development.

The Zika virus, a mosquito-borne infection, has been shown to be a cause of microcephaly and other severe fetal brain defects. For pregnant women, it is especially important to reliably identify Zika virus infection in a timely manner, but current methods show high false positive rates and can take weeks to return test results. The compact and portable Agile R100 represents a potential methodology to identify Zika infection promptly.

Curematch Co-founders Study the molecular Alterations of Genes to Develop Personalized Cancer Therapy Options

CureMatch, a Serra Capital III portfolio company, has recently published a study in the journal of Cancer Biology & Therapy. CureMatch is a digital health company focused on personalized medicine and combination therapy in oncology.

The study conducted by CureMatch highlighted the role of a specific molecular mutation in eosinophilic cystitis, and how their methods might better treat this type of condition. 


Chicago Timmy Awards Selects Label Insight a Best Tech Startup Finalist

Label Insight, a Serra Capital II portfolio company, was recently ecognized by Tech in Motion as one of the best technology startups in Chicago. Label Insight is the market leader for transparency, enabling access to complete and accurate product information for more than 400,000 products, representing 80 percent of the top purchased CPG products in the U.S.

"The Timmy Awards aim to celebrate the companies and managers that make that technological innovation possible," said Mandy Walker, director of marketing at Tech in Motion and Motion Recruitment Partners. "Since the Timmy Awards were created in 2015, over 400 finalists have been celebrated for creating work environments that enable growth in the technology of various industries."


HomeBay Rewriting the Rules of Engagement in Real Estate

HomeBay, a Serra Capital III portfolio company, was recently listed in a piece on The Lenders Network as one of five fintech companies that is changing the way people engage in real estate. HomeBay helps sellers to navigate the real estate process via automated & live help to make the listing, selling and closing processes faster, easier and less stressful. The company also puts homes in front of millions of buyers by syndicating the listings to the MLS and the most popular real estate sites across the web.

The article features HomeBay's platform, which allows regular homeowners to sell like professionals without the high costs of engaging a real estate agent.


WhiteFox’s counter-drone technology tested this week at U.S. military base

WhiteFox Defense Technologies, a Serra Capital III portfolio company, recently demonstrated their flagship product, the DroneFox, to a range of U.S. military leaders during the Joint Interagency Field Experimentation (JIFX) program. 

Drones pose a present and evolving danger to people and property. WhiteFox Defense Technologies, Inc. has developed a comprehensive, intuitive, portable drone interception device called the DroneFox to counteract these threats.


Hercutech's Breakout Year

Hercutech, a Serra Capital I and II company, was featured on on August 21. Hercutech manufactures and markets HercuWall, a panelized concrete wall system that is used in lieu of concrete block wall and wood frame construction in new residential and commercial building structures. HercuWall is the product of years of engineering, development, and testing resulting in a building technology that exceeds concrete block wall construction in strength, performance and speed of installation.

After 8 years of hard work getting their ground-breaking technology to the market, CEO Michael Neimann is finally getting his breakout year. If the product is adopted, it is one that "could change, in pretty short order, a lot of the conversation we've been having about home builders and economic productivity."


Serra Capital Invests in CureMatch

CureMatch, a digital health company focusing on personalized medicine and combination therapy in oncology, is Serra Capital III's 13th investment. Serra is participating in the company's Bridge to Series A round. 

"CureMatch represents a unique, breakthrough opportunity in the treatment of cancer, a disease that touches all of our lives in some way," said Steve Beck, Managing Partner at Serra Venture's San Diego office. "The company's solution resides at the intersection of precision medicine and actionable intelligence extracted from big data. We're confident that the CureMatch team is poised to lead the way in personalized cancer treatment, and we are thrilled to add them to the Serra Ventures' portfolio."


Serra Ventures Publishes New White Paper on SBIC

The Serra Capital III (SBIC) fund officially launched fundraising efforts in July 2017 after receiving the “green-light” letter from the SBA. With a rigorous underwriting and approval process, the Serra Ventures team is very pleased to be accepted into this program and eager to begin accepting commitments. Throughout this process, we have been approached with a variety of questions. What is an SBIC Fund? Why invest in an SBIC Fund? How does the SBIC Fund differ from its sister fund, Serra Capital III? This high level white paper will address these questions - and explain why an SBIC Fund is attractive for banks and non-bank investors alike.